TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22931971

Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush
Number of subjects: 75

Group type: COMPARATOR
Intervention: Provisional side branch (PS) stenting
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both DK and PS groups
Number of subjects: 75
Study: 19915080

Group type: EXPERIMENTAL
Intervention: 4 individualized counselor-led MI sessions and nicotine replacement therapy (NRT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 4 general health education sessions, self-help materials, and NRT
Number of subjects: 122
Study: 17300536

Group type: EXPERIMENTAL
Intervention: Motivational interviewing session
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study: 15506574

Group type: EXPERIMENTAL
Intervention: Pen-tablet computers for data collection
Number of subjects: 168
Study: 16325299

Group type: EXPERIMENTAL
Intervention: Insulin infusion algorithm
Number of subjects: 60
Study: 10579701

Group type: EXPERIMENTAL
Intervention: Community-based health services (health-oriented services)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Individual, fragmented, disease-oriented approaches to care
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Integrated services aimed at health determinants
Number of subjects: 12
Study: 8815557

Group type: EXPERIMENTAL
Intervention: Functional electro-stimulation (FES)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Perineal floor rehabilitation with electrostimulation
Number of subjects: 44
Study: 1804386

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-leucovorin combination with allopurinol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5-fluorouracil-leucovorin combination without allopurinol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Responders with colon cancer
Number of subjects: 50
Study: 6376916

Group type: EXPERIMENTAL
Intervention: 30-g protein-restricted diet supplemented by keto acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31214846

Group type: EXPERIMENTAL
Intervention: Three-step yoga program for T2DM, details on dosage and duration not specified.
Number of subjects: 0
Study: 29676600

Group type: EXPERIMENTAL
Intervention: Eye-tracking while browsing the Internet for vaccination information
Number of subjects: 56
Study: 28558000

Group type: EXPERIMENTAL
Intervention: Working memory training intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Processing speed training active control condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 0
Study: 26776879

Group type: EXPERIMENTAL
Intervention: Clinutren Protect(®) (CP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control isocaloric diet (without TGF-β2 or glutamine)
Number of subjects: 201
Study: 25116969

Group type: EXPERIMENTAL
Intervention: Levia® localized NB‐UVB phototherapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Visible light (sham treatment)
Number of subjects: 21
Study: 23017045

Group type: EXPERIMENTAL
Intervention: Resourcefulness Training (RT)
Number of subjects: 126
Study: 19607666

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapy led exercise class
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fitness instructor led exercise class
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiotherapist led intervention (Strand B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group intervention led by Physiotherapist (Strand B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group yoga intervention (Strand B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no change in exercise habits)
Number of subjects: 0
Study: 17768662

Group type: EXPERIMENTAL
Intervention: Axin overexpression in BE1 cells (BE1-axin cells)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (non-transfected BE1 cells)
Number of subjects: 107
Study: 15035598

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Inhaled corticosteroid therapy)
Number of subjects: 0
Study: 12453333

Group type: EXPERIMENTAL
Intervention: Postoperative chemoradiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-based chemotherapy with radiation
Number of subjects: 0
Study: 11475715

Group type: EXPERIMENTAL
Intervention: Buyang Huanwu Decoction (BHD) combined with western medicine (prednisone acetate and cytoxan)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Western medicine (prednisone acetate and cytoxan) with aspirin and persantin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 70
Study: 7544731

Group type: EXPERIMENTAL
Intervention: Finasteride treatment for 5 years
Number of subjects: 55
Study: 31112079

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 µg applied vaginally 10 hours and 4 hours prior to IUD insertion
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo tablet applied vaginally 10 hours and 4 hours prior to IUD insertion
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28319872

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen (ITB) bolus injection, 50-μg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 25878371

Group type: EXPERIMENTAL
Intervention: Single dose (500 mg) of IV methylprednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 days of oral prednisolone
Number of subjects: 0
Study: 23261871

Group type: EXPERIMENTAL
Intervention: High energy-dense (high-ED) food cues in fed state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low energy-dense (low-ED) food cues in fed state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High energy-dense (high-ED) food cues in fasted state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low energy-dense (low-ED) food cues in fasted state
Number of subjects: 0
Study: 21612952

Group type: EXPERIMENTAL
Intervention: Custom-made metal postcore (CMPC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Prefabricated fiber postcore (PFPC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Custom-made fiber postcore (CFPC)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Buccally tilted restorations
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Lingually tilted restorations
Number of subjects: 75
Study: 19918859

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 73

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN) ointment
Number of subjects: 73
Study: 17005502

Group type: EXPERIMENTAL
Intervention: OPTIMISE programme (treatment group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 12773076

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 0
Study: 11072556

Group type: EXPERIMENTAL
Intervention: Fiber/pectin
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fiber-free/placebo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fiber/placebo
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fiber
Number of subjects: 44
Study: 9863109

Group type: EXPERIMENTAL
Intervention: RBUD-1 (a preparation of Chinese herbal medicine)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Composite prescription of Western and Chinese medicine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Lasix or mineral water (control group)
Number of subjects: 122
Study: 8280685

Group type: EXPERIMENTAL
Intervention: 44 micrograms NODS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 74 micrograms NODS
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 124 micrograms NODS
Number of subjects: 28

Group type: COMPARATOR
Intervention: 35 microliters of 0.5% proxymetacaine drops (175 micrograms)
Number of subjects: 28
Study: 3549583

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 32
Study: 31343518

Group type: COMPARATOR
Intervention: No virtual opponent (NO)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low athlete‐opponent interdependency (OP‐IND)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High athlete‐opponent interdependency (OP‐DEP)
Number of subjects: 12
Study: 30457358

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27789414

Group type: EXPERIMENTAL
Intervention: ASBI implementation program (including e-learning module, tailored feedback module, and environmental support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASBI implementation program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (GPs not receiving the ASBI implementation program)
Number of subjects: 0
Study: 24597472

Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux (3 mg weekly for the first 7 weeks, then 2 mg, adjusted to 1.5 mg for certain patients)
Number of subjects: 3773

Group type: COMPARATOR
Intervention: Warfarin (daily with dose adjustment to maintain INR between 2.0 and 3.0)
Number of subjects: 3773

Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux
Number of subjects: 3773

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3773
Study: 22613182

Group type: EXPERIMENTAL
Intervention: Internet-based screening and brief intervention via eScreen.se
Number of subjects: 202

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 202
Study: 21169087

Group type: EXPERIMENTAL
Intervention: PET scan before treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PET scan after 6 months of treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clinical criteria
Number of subjects: 35
Study: 19932833

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 1% gel (DSG) 4 g, applied 4 times daily for 12 weeks
Number of subjects: 492

Group type: COMPARATOR
Intervention: Vehicle (placebo) 4 g, applied 4 times daily for 12 weeks
Number of subjects: 492
Study: 15899444

Group type: EXPERIMENTAL
Intervention: Tropicamide 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cyclopentolate 1%
Number of subjects: 30
Study: 12609785

Group type: EXPERIMENTAL
Intervention: LHA formulation (2-hydroxy-5-octanoyl benzoic acid), applied twice daily for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 14
Study: 10338051

Group type: EXPERIMENTAL
Intervention: Alkalinized local anaesthesia (LA) solution (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-alkalinized local anaesthesia (LA) solution (n = 21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMLA cream with local anaesthesia and patient-controlled analgesia with alfentanil
Number of subjects: 40
Study: 8520498

Group type: EXPERIMENTAL
Intervention: Intron A (3 mega units/m2 s.c. three times weekly)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intron A
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Intron A (started in 45 patients at a median of 62 days after HDM)
Number of subjects: 84
Study: 1951587

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120
Study: 7203334

Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 micrograms/kg body weight and 0.5 micrograms/kg body weight)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Neostigmine (0.5 mg per single dose)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dihydroergotamine (1 mg)
Number of subjects: 30
Study: 31444080

Group type: EXPERIMENTAL
Intervention: Mini-monovision group (nondominant eye targeted for -0.50 D)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Emmetropia group (both eyes targeted for emmetropia)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 29725805

Group type: EXPERIMENTAL
Intervention: TURBT + tamsulosin (Group 1)
Number of subjects: 95

Group type: COMPARATOR
Intervention: TURBT + TURP (Group 2)
Number of subjects: 95
Study: 27399494

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery to a surgical cavity (SRS‐cav)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Observation (OBS)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: SRS‐cav
Number of subjects: 131

Group type: COMPARATOR
Intervention: OBS
Number of subjects: 131
Study: 24597650

Group type: EXPERIMENTAL
Intervention: RehabMaster intervention (30 minutes per day for two weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: RehabMaster intervention plus conventional occupational therapy (10 sessions)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional occupational therapy only (OT-only group)
Number of subjects: 23
Study: 22204928

Group type: EXPERIMENTAL
Intervention: Cortisol AUCi
Number of subjects: 20
Study: 20073567

Group type: EXPERIMENTAL
Intervention: Integrated Supported Employment (ISE), n = 58
Number of subjects: 189

Group type: COMPARATOR
Intervention: Individual Placement and Support (IPS), n = 65
Number of subjects: 189

Group type: COMPARATOR
Intervention: Traditional Vocational Rehabilitation (TVR), n = 66
Number of subjects: 189
Study: 17331969

Group type: EXPERIMENTAL
Intervention: Noninvasive positive-pressure ventilation (NPPV) during walking
Number of subjects: 20

Group type: COMPARATOR
Intervention: No noninvasive positive-pressure ventilation (without NPPV) during walking
Number of subjects: 20
Study: 15914127

Group type: EXPERIMENTAL
Intervention: St. John's Wort 300 mg three times daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-dose OC (Loestrin 1/20) with placebo
Number of subjects: 16
Study: 12626213

Group type: EXPERIMENTAL
Intervention: Low-dose estrogen-progestin therapy (1 mg 17beta-estradiol with 500 micro g norethisterone acetate daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pravastatin (20 mg daily)
Number of subjects: 72
Study: 10337434

Group type: EXPERIMENTAL
Intervention: Patanol (olopatadine hydrochloride 0.1% ophthalmic solution)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Claritin (loratadine, 10 mg tablet)
Number of subjects: 15
Study: 8527539

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 3 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg daily for 3 days)
Number of subjects: 42
Study: 2257072

Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone (somatropin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (treated and control)
Number of subjects: 12
Study: 7279423

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 29155291

Group type: EXPERIMENTAL
Intervention: QUAL‐EC‐P questionnaire
Number of subjects: 183
Study: 27956565

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg/d)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 24425697

Group type: EXPERIMENTAL
Intervention: Emergency medical services treatment for ACS
Number of subjects: 871
Study: 23727163

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 2876

Group type: COMPARATOR
Intervention: No IPC (control group)
Number of subjects: 2876

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 2876
Study: 20417572

Group type: EXPERIMENTAL
Intervention: Maintenance group (optimal therapeutic doses continued throughout the study)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 26-week group (optimal therapeutic doses continued for 26 weeks, followed by a 50% dose reduction maintained until the end of the study)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 4-week group (optimal therapeutic doses continued for 4 weeks, followed by a 50% dose reduction maintained until the end of the study)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: All three treatment groups
Number of subjects: 404
Study: 18355330

Group type: EXPERIMENTAL
Intervention: Raisin consumption (90 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isocaloric placebo (264 kcal/day)
Number of subjects: 17
Study: 16627548

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Supportive therapy plus placebo medication
Number of subjects: 28
Study: 12648967

Group type: EXPERIMENTAL
Intervention: Postnatal home visits by nurse-midwives (5 structured visits)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 139
Study: 11034122

Group type: EXPERIMENTAL
Intervention: Branded toothbrush 1
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Branded toothbrush 2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Toothbrush with convex filament head arrangement
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no brushing)
Number of subjects: 18
Study: 9103748

Group type: EXPERIMENTAL
Intervention: Anger treatment (12-session cognitive-behavioral treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Routine clinical care control
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Follow-up (18 months)
Number of subjects: 15
Study: 1391667

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 3902480

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside (40 mg/day i.m. injection) for 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31112941

Group type: EXPERIMENTAL
Intervention: aLiFE program (Lifestyle‐integrated Functional Exercise)
Number of subjects: 30
Study: 30172407

Group type: EXPERIMENTAL
Intervention: Cr supplementation (0.05 mg of Cr/kg of body weight0.75)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no Cr supplement; Cr‐)
Number of subjects: 24
Study: 27310977

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (500 mg bid), levofloxacin (500 mg once daily), omeprazole (40 mg bid), doxycycline (100 mg twice daily) for 14 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Nitazoxanide-based regimen
Number of subjects: 100
Study: 24902655

Group type: EXPERIMENTAL
Intervention: Individualized goal-directed therapy (IGDT) with transthoracic echocardiography (TTE) and pulse-contour device (FloTrac™)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Individualized goal-directed therapy (IGDT)
Number of subjects: 50
Study: 23558875

Group type: EXPERIMENTAL
Intervention: ASA therapy
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Plasma SA concentration
Number of subjects: 293
Study: 20816468

Group type: EXPERIMENTAL
Intervention: Antimigrainous medication for treating single attacks and preventing recurring attacks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18755550

Group type: EXPERIMENTAL
Intervention: High time spent with smoking parents
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Low time spent with smoking parents
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Non-smoking parents
Number of subjects: 67

Group type: COMPARATOR
Intervention: Overall correlation with parental smoking exposure
Number of subjects: 67
Study: 15725422

Group type: EXPERIMENTAL
Intervention: 200 mg levodopa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12882902

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 102
Study: 10429625

Group type: EXPERIMENTAL
Intervention: Adjuvant doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide and continuous infusion of etoposide with growth factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant ifosfamide and doxorubicin treatment after primary surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy for localized resectable STS
Number of subjects: 0
Study: 8666123

Group type: EXPERIMENTAL
Intervention: Menorest® (adhesive matrix transdermal system) used in combination with dydrogesterone for 12 days in each cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menorest®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menorest® (twice weekly application)
Number of subjects: 0
Study: 1869005

Group type: EXPERIMENTAL
Intervention: Iron medication (2 x 1 Aktiferrin comp. Kps. during pregnancy starting from the 22nd week)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No medication during pregnancy (control group)
Number of subjects: 103
Study: 6718333

Group type: EXPERIMENTAL
Intervention: Oxytocin (administered intravenously and/or intranasally)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (double blind)
Number of subjects: 27
Study: 30260458

Group type: EXPERIMENTAL
Intervention: MCT-JTC (Metacognitive Training for Jumping to Conclusions)
Number of subjects: 37

Group type: COMPARATOR
Intervention: AC (Attention Control)
Number of subjects: 37
Study: 30063813

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 161
Study: 27411267

Group type: EXPERIMENTAL
Intervention: Compression dressing therapy (observation group, n = 17)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Ordinary dressing therapy (control group, n = 17)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 24842697

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33357

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33357
Study: 23062629

Group type: EXPERIMENTAL
Intervention: Direct mail
Number of subjects: 830

Group type: COMPARATOR
Intervention: Control
Number of subjects: 830
Study: 20394043

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 164